JP2017525343A5 - - Google Patents

Download PDF

Info

Publication number
JP2017525343A5
JP2017525343A5 JP2017501280A JP2017501280A JP2017525343A5 JP 2017525343 A5 JP2017525343 A5 JP 2017525343A5 JP 2017501280 A JP2017501280 A JP 2017501280A JP 2017501280 A JP2017501280 A JP 2017501280A JP 2017525343 A5 JP2017525343 A5 JP 2017525343A5
Authority
JP
Japan
Prior art keywords
hil
antigen
binding
nmol
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017501280A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525343A (ja
JP7209464B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/055226 external-priority patent/WO2016005950A1/en
Publication of JP2017525343A publication Critical patent/JP2017525343A/ja
Publication of JP2017525343A5 publication Critical patent/JP2017525343A5/ja
Application granted granted Critical
Publication of JP7209464B2 publication Critical patent/JP7209464B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017501280A 2014-07-10 2015-07-10 ヒトインターロイキン-2に対する免疫刺激性モノクローナル抗体 Active JP7209464B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14176619.6 2014-07-10
EP14176619 2014-07-10
PCT/IB2015/055226 WO2016005950A1 (en) 2014-07-10 2015-07-10 Immune-stimulating monoclonal antibodies against human interleukin-2

Publications (3)

Publication Number Publication Date
JP2017525343A JP2017525343A (ja) 2017-09-07
JP2017525343A5 true JP2017525343A5 (OSRAM) 2018-08-16
JP7209464B2 JP7209464B2 (ja) 2023-01-20

Family

ID=51162588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017501280A Active JP7209464B2 (ja) 2014-07-10 2015-07-10 ヒトインターロイキン-2に対する免疫刺激性モノクローナル抗体

Country Status (9)

Country Link
US (2) US10894828B2 (OSRAM)
EP (2) EP3166973B1 (OSRAM)
JP (1) JP7209464B2 (OSRAM)
CN (1) CN106604932B (OSRAM)
AU (1) AU2015287227B2 (OSRAM)
CA (1) CA2954476C (OSRAM)
DK (1) DK3166973T3 (OSRAM)
ES (2) ES2779977T3 (OSRAM)
WO (1) WO2016005950A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018008592A (es) * 2016-01-11 2018-12-10 Novartis Ag Anticuerpos monoclonales humanizados inmunoestimulantes contra interleucina-2 humana, y proteinas de fusion de los mismos.
JP2019534710A (ja) 2016-09-28 2019-12-05 ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー インターロイキン2に結合する抗体およびその使用
GB201621806D0 (en) * 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
CN110913873A (zh) * 2017-02-23 2020-03-24 希望之城 用于cd8+t细胞的体内扩增并预防或治疗gvhd的方法
EP3600421A4 (en) * 2017-03-23 2021-01-06 The Trustees of The University of Pennsylvania ANTI-C5A ANTIBODIES AND USES OF THEM
RU2745451C1 (ru) * 2017-05-25 2021-03-25 Инститьют Фор Бейсик Сайенс Антитела к человеческому интерлейкину-2 и их применение
AU2019322487B2 (en) 2018-03-19 2024-04-18 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
CN115768483A (zh) 2020-01-13 2023-03-07 西纳福克斯股份有限公司 抗体与免疫细胞衔接器的缀合物
IL295210B2 (en) * 2020-02-16 2024-04-01 Aulos Bioscience Inc Transgenic antibodies against 2–IL
CA3189257A1 (en) * 2020-08-18 2022-02-24 Universitat Zurich A cd25-biased anti-il-2 antibody
US20250262314A1 (en) 2021-02-08 2025-08-21 Synaffix B.V. Multifunctional antibodies
JP2024539749A (ja) 2021-10-14 2024-10-29 ラッティコン (スージョウ) バイオファーマシューティカルズ カンパニー リミテッド 新規な抗体-サイトカイン融合タンパク質及びその製造方法と使用
US11773160B1 (en) 2022-08-05 2023-10-03 Anaveon AG Immune-stimulating IL-2 fusion proteins
CN119775409B (zh) * 2025-03-05 2025-07-11 深圳真实生物医药科技有限公司 靶向sost的抗体及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA849910B (en) * 1983-12-23 1985-09-25 Hoffmann La Roche Purification of recombinant interleukin-2
JPS62269698A (ja) * 1986-03-17 1987-11-24 エフ.ホフマン ― ラ ロシュ アーゲー Il−2蛋白質に対するモノクロ−ナル抗体
DE69738749D1 (de) 1996-08-16 2008-07-17 Schering Corp Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
EP2572715A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
EP1765402A2 (en) 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
US7964707B2 (en) 2005-06-01 2011-06-21 Micromet Ag Anti-IL2 antibodies
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
AU2007214426A1 (en) * 2006-02-16 2007-08-23 Nascent Biologics, Inc. Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject
CN101045923B (zh) * 2006-03-31 2011-11-23 沈阳三生制药有限责任公司 生产一种白细胞介素类似物的方法
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
PT3042917T (pt) 2010-08-12 2018-05-02 Lilly Co Eli Anticorpos do péptido beta amilóide anti-n3pglu e seus usos
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
WO2013157105A1 (ja) 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ5ac特異的ヒト化抗体およびその利用
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
WO2015109212A1 (en) * 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof

Similar Documents

Publication Publication Date Title
JP2017525343A5 (OSRAM)
JP2022177090A5 (OSRAM)
JP2018536393A5 (OSRAM)
PE20210342A1 (es) Anticuerpos anti-sirpa y metodos de utilizacion de los mismos
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
JP2020500538A5 (OSRAM)
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
MY198942A (en) Anti-tau antibodies and methods of use
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
JP2017505125A5 (OSRAM)
JP2019528683A5 (OSRAM)
RU2014108309A (ru) Антиполиубиквитиновые антитела и способы применения
JP2020537520A5 (OSRAM)
PE20240802A1 (es) Anticuerpos multiespecificos con especificidad para il-4r e il-31
NZ628943A (en) Human antibodies to clostridium difficile toxins
RU2016107814A (ru) Новое антитело к tslp-рецептору человека
AR103713A1 (es) Anticuerpos contra tau y sus usos
JP2016520595A5 (OSRAM)
AR104906A1 (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
JP2017521054A5 (OSRAM)
HRP20192038T1 (hr) Protutijela receptora anti-epidermalnog faktora rasta (egfr)
RU2017134043A (ru) Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью
RU2014145536A (ru) Антитело против adamts-5, его производные и их применение
RU2016143552A (ru) Гуманизированные антитела к антигену Томсена-Фриденрайха
RU2016129166A (ru) Антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой терапии